Australia phased out AstraZeneca in March last year (2023)
In Australia, the last case of TTS reported by the Therapeutic Goods Administration was in December 2021.1 At that time, the rates of TTS were estimated to be:
about 2 per 100,000 people vaccinated with AstraZeneca aged 60 years or older.
about 2 to 3 per 100,000 people vaccinated with AstraZeneca under 60 years of age.
A range of severity of illness was reported in Australia. Some cases were relatively mild, some had significant morbidity, and some were fatal.
The overall case fatality rate in Australia was lower than reported internationally.
This was likely due to increased detection due to increased awareness, as well as early diagnosis and treatment.
Most issues in the few cases presented within a month ( 4 - 42 days, mostly sooner than later ).
https://www.health.gov.au/our-work/covid-19-vaccines/advice-...
(Current as of January 2024)